建议完善我国罕用药医保遴选标准，引入风险共担机制及规范罕用药的使用和报销。
It is recommended to perfect orphan drugs medical insurance access standard, introduce risk-sharing mechanism and standardize the use of orphan drugs and reimbursement in China.
摘要：目的：介绍澳大利亚高值药物医保准入机制，为我国罕用药医保准入的完善提供建议。
ABSTRACT: OBJECTIVE: to introduce high-value drug insurance access mechanism in Australia, and to provide suggestion for improving orphan drug medical insurance access in China.
罕用药研发主要面对两方面的困难，一方面是病患人数少，商业价值有限，另一方面是病例不足。
The main difficulties of Orphan Drug Research and Development is by both sides, on the one hand, the small number of patients, limited commercial value, on the other hand, insufficient cases.
罕用药研发主要面对两方面的困难，一方面是病患人数少，商业价值有限，另一方面是病例不足。
The main difficulties of Orphan Drug Research and Development is by both sides, on the one hand, the small number of patients, limited commercial value, on the other hand, insufficient cases.
应用推荐